Oppenheimer & Co. Inc. trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 4.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,124 shares of the medical equipment provider’s stock after selling 633 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Boston Scientific Corporation were worth $392,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the business. Swiss National Bank boosted its holdings in shares of Boston Scientific Corporation by 2.9% in the second quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock worth $154,814,000 after buying an additional 156,800 shares during the period. Bronfman E.L. Rothschild L.P. boosted its holdings in shares of Boston Scientific Corporation by 14.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock worth $160,000 after buying an additional 720 shares during the period. Commerce Bank boosted its holdings in shares of Boston Scientific Corporation by 17.7% in the second quarter. Commerce Bank now owns 9,803 shares of the medical equipment provider’s stock worth $272,000 after buying an additional 1,471 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Boston Scientific Corporation by 2.4% in the second quarter. Principal Financial Group Inc. now owns 2,031,611 shares of the medical equipment provider’s stock worth $56,317,000 after buying an additional 47,667 shares during the period. Finally, Greenwood Capital Associates LLC boosted its holdings in shares of Boston Scientific Corporation by 1.1% in the second quarter. Greenwood Capital Associates LLC now owns 53,330 shares of the medical equipment provider’s stock worth $1,478,000 after buying an additional 564 shares during the period. Institutional investors own 90.52% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Boston Scientific Corporation (BSX) Holdings Lowered by Oppenheimer & Co. Inc.” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/17/boston-scientific-corporation-bsx-holdings-lowered-by-oppenheimer-co-inc.html.

In other Boston Scientific Corporation news, EVP Timothy A. Pratt sold 10,104 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $27.46, for a total transaction of $277,455.84. Following the completion of the transaction, the executive vice president now owns 185,742 shares of the company’s stock, valued at approximately $5,100,475.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP John Bradley Sorenson sold 2,100 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $27.15, for a total value of $57,015.00. Following the transaction, the senior vice president now directly owns 18,880 shares of the company’s stock, valued at approximately $512,592. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 275,257 shares of company stock valued at $7,512,394. Insiders own 0.74% of the company’s stock.

Several research analysts have commented on BSX shares. Royal Bank Of Canada raised their target price on shares of Boston Scientific Corporation from $29.00 to $31.00 and gave the stock an “outperform” rating in a report on Friday, June 9th. BidaskClub upgraded shares of Boston Scientific Corporation from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. Wells Fargo & Company reiterated an “outperform” rating and issued a $31.00 target price (up from $29.50) on shares of Boston Scientific Corporation in a report on Friday, June 16th. BMO Capital Markets reiterated a “buy” rating and issued a $30.00 target price on shares of Boston Scientific Corporation in a report on Wednesday, June 21st. Finally, Needham & Company LLC raised their target price on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $29.88.

Shares of Boston Scientific Corporation (BSX) opened at 28.93 on Friday. The firm has a 50-day moving average of $27.28 and a 200-day moving average of $26.52. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $29.40. The firm has a market capitalization of $39.70 billion, a PE ratio of 51.75 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the firm posted $0.27 EPS. The business’s revenue was up 6.2% on a year-over-year basis. On average, equities research analysts anticipate that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.

Boston Scientific Corporation Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.